{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:21:23Z","timestamp":1793391683905,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:00:00Z","timestamp":1771372800000},"content-version":"vor","delay-in-days":309,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The optimal timing for prescribing guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) during acute decompensated heart failure (ADHF) remains uncertain. This study evaluated the real-world impact of early in-hospital quadruple GDMT prescription in ADHF patients with HFrEF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p>In this retrospective cohort study using the Institutional aCute descompensAted heaRt failUre regiStry (ICARUS), we analysed 2051 HFrEF patients (71% male, median age 68 years) hospitalized for ADHF between June 2022 and March 2024. Early quadruple therapy was defined as the prescription of beta-blockers, angiotensin-converting enzyme inhibitors (ACEIs)\/angiotensin receptor blockers (ARBs)\/angiotensin receptor\u2013neprilysin inhibitors (ARNIs), mineralocorticoid receptor antagonists (MRAs) and sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) within 48 h of admission. Among included patients, 898 (43.8%) received early quadruple therapy. Using optimal full matching propensity score methodology, early quadruple therapy was associated with lower 30 day mortality\/rehospitalization [relative risk (RR) 0.73; 95% confidence interval (CI) 0.55\u20130.97, P = 0.028], reduced in-hospital mortality (RR 0.29; 95% CI 0.15\u20130.56, P &amp;lt; 0.001) and shorter hospital stay (\u03b2 = \u22122.65 days; 95% CI \u22123.67 to \u22121.63, P &amp;lt; 0.001). Patients receiving early quadruple therapy showed higher rates of GDMT continuation at discharge (RR 3.82; 95% CI 3.01\u20134.86, P &amp;lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this HFrEF cohort, early initiation of comprehensive GDMT during ADHF hospitalization was associated with improved clinical outcomes. Future randomized trials including patients across the full spectrum of ejection fraction are needed to validate these findings and determine their applicability to other heart failure phenotypes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.15286","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:52:31Z","timestamp":1744717951000},"page":"2814-2826","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Early Prescription of Quadruple Therapy in Acute Decompensated Heart Failure with Reduced Ejection Fraction: A Propensity Score-Matched Analysis"],"prefix":"10.1093","volume":"12","author":[{"given":"Luis E.","family":"Echeverr\u00eda","sequence":"first","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyda Z.","family":"Rojas","sequence":"additional","affiliation":[{"name":"Research Center, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Yarlady","family":"Serrano-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Botero","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Andrea","family":"Garc\u00eda-Rueda","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Torres-Bustamante","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Ivonne","family":"Ca\u00f1\u00f3n-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Sebasti\u00e1n","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Hurtado-Ortiz","sequence":"additional","affiliation":[{"name":"Epidemiology Unit, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime A.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1396-5042","authenticated-orcid":false,"given":"Sergio A.","family":"G\u00f3mez-Ochoa","sequence":"additional","affiliation":[{"name":"Heart Failure and Transplant Clinic, Fundaci\u00f3n Cardiovascular de Colombia , Floridablanca ,","place":["Colombia"]},{"name":"Department of General Internal Medicine and Psychosomatics, Heidelberg University Hospital , Heidelberg ,","place":["Germany"]},{"name":"School of Medicine, Universidad Industrial de Santander , Bucaramanga ,","place":["Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2026021804142077700_ehf215286-bib-0001","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/0885066616669494","article-title":"Acute decompensated heart failure","volume":"33","author":"Hammond","year":"2018","journal-title":"J Intensive Care Med"},{"key":"2026021804142077700_ehf215286-bib-0002","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s41669-023-00431-0","article-title":"Hospital resource utilization and costs in patients with heart failure in France","volume":"7","author":"Chemouni","year":"2023","journal-title":"Pharmacoecon Open"},{"key":"2026021804142077700_ehf215286-bib-0003","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2459\/JCM.0000000000001581","article-title":"Clinical and prognostic implications of heart failure hospitalization in patients with advanced heart failure","volume":"25","author":"Pagnesi","year":"2024","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"2026021804142077700_ehf215286-bib-0004","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/HPC.0000000000000031","article-title":"Challenges in acute heart failure clinical management: Optimizing care despite incomplete evidence and imperfect drugs","volume":"14","author":"Teichman","year":"2015","journal-title":"Crit Pathw Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0005","doi-asserted-by":"publisher","first-page":"74","DOI":"10.15420\/cfr.2019.3.2","article-title":"The limitations of symptom-based heart failure management","volume":"5","author":"Papadimitriou","year":"2019","journal-title":"Card Fail Rev"},{"key":"2026021804142077700_ehf215286-bib-0006","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s10741-023-10325-2","article-title":"Guideline-directed medical therapy for HFrEF: Sequencing strategies and barriers for life-saving drug therapy","volume":"28","author":"Malgie","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2026021804142077700_ehf215286-bib-0007","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s40256-024-00646-4","article-title":"Advancing guideline-directed medical therapy in heart failure: Overcoming challenges and maximizing benefits","volume":"24","author":"Zhang","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"key":"2026021804142077700_ehf215286-bib-0008","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0009","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0010","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0011","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0012","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"2026021804142077700_ehf215286-bib-0013","doi-asserted-by":"publisher","first-page":"e895","DOI":"10.1161\/CIR.0000000000001063","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"2026021804142077700_ehf215286-bib-0014","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804142077700_ehf215286-bib-0015","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/eurheartj\/ehac530","article-title":"Impact of empagliflozin on decongestion in acute heart failure: The EMPULSE trial","volume":"44","author":"Biegus","year":"2023","journal-title":"Eur Heart J"},{"key":"2026021804142077700_ehf215286-bib-0016","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"key":"2026021804142077700_ehf215286-bib-0017","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0018","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.028820","article-title":"Clinical profile, health care costs, and outcomes of patients hospitalized for heart failure with severely reduced ejection fraction","volume":"12","author":"Harrington","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"2026021804142077700_ehf215286-bib-0019","doi-asserted-by":"publisher","first-page":"L38","DOI":"10.1093\/eurheartjsupp\/suac120","article-title":"Getting ahead of the game: In-hospital initiation of HFrEF therapies","volume":"24","author":"Biegus","year":"2022","journal-title":"Eur Heart J Suppl"},{"key":"2026021804142077700_ehf215286-bib-0020","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","article-title":"Medical therapy for heart failure with reduced ejection fraction: The CHAMP-HF registry","volume":"72","author":"Greene","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0021","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.cardfail.2023.09.005","article-title":"Medical therapy before, during and after hospitalization in Medicare beneficiaries with heart failure and diabetes: Get With The Guidelines\u2014Heart Failure registry","volume":"30","author":"Bhatt","year":"2024","journal-title":"J Card Fail"},{"key":"2026021804142077700_ehf215286-bib-0022","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026021804142077700_ehf215286-bib-0023","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014A metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"2026021804142077700_ehf215286-bib-0024","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"2026021804142077700_ehf215286-bib-0025","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1198\/016214504000000647","article-title":"Full matching in an observational study of coaching for the SAT","volume":"99","author":"Hansen","year":"2004","journal-title":"J Am Stat Assoc"},{"key":"2026021804142077700_ehf215286-bib-0026","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1002\/sim.6602","article-title":"Optimal full matching for survival outcomes: A method that merits more widespread use","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"2026021804142077700_ehf215286-bib-0027","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109112","article-title":"Bias due to sample selection in propensity score matching for a supportive housing program evaluation in New York City","volume":"9","author":"Lim","year":"2014","journal-title":"PLoS ONE"},{"key":"2026021804142077700_ehf215286-bib-0028","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","article-title":"MatchIt: Nonparametric preprocessing for parametric causal inference","volume":"42","author":"Ho","year":"2011","journal-title":"J Stat Softw"},{"key":"2026021804142077700_ehf215286-bib-0029","first-page":"464","article-title":"Heart failure: A class review of pharmacotherapy","volume":"42","author":"Shah","year":"2017","journal-title":"P T"},{"key":"2026021804142077700_ehf215286-bib-0030","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0031","doi-asserted-by":"publisher","first-page":"S52","DOI":"10.1002\/clc.23845","article-title":"Improving implementation of evidence-based therapies for heart failure","volume":"45","author":"DeVore","year":"2022","journal-title":"Clin Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0032","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020012","article-title":"Lower in-hospital mortality with beta-blocker use at admission in patients with acute decompensated heart failure","volume":"10","author":"Tamaki","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2026021804142077700_ehf215286-bib-0033","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1570161114666160822155440","article-title":"Beta-blockers are associated with decreased in-hospital mortality and stroke in acute decompensated heart failure: Findings from a retrospective analysis of a 22-year registry in the Middle East (1991-2013)","volume":"15","author":"Abi Khalil","year":"2017","journal-title":"Curr Vasc Pharmacol"},{"key":"2026021804142077700_ehf215286-bib-0034","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014915","article-title":"Non-withdrawal of beta blockers in acute decompensated chronic and de novo heart failure with reduced ejection fraction in a prospective multicentre study of patients with acute heart failure in the Middle East","volume":"7","author":"Abi Khalil","year":"2017","journal-title":"BMJ Open"},{"key":"2026021804142077700_ehf215286-bib-0035","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00380-023-02304-2","article-title":"Timing of prescription of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers in patients hospitalized for acute heart failure with reduced\/mildly reduced ejection fraction: A retrospective analysis","volume":"39","author":"Ishii","year":"2024","journal-title":"Heart Vessels"},{"key":"2026021804142077700_ehf215286-bib-0036","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.2147\/IJGM.S310309","article-title":"Continuation of angiotensin converting enzyme inhibitors in acute heart failure","volume":"14","author":"AlHabeeb","year":"2021","journal-title":"Int J Gen Med"},{"key":"2026021804142077700_ehf215286-bib-0037","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004675","article-title":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction","volume":"6","author":"Gilstrap","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2026021804142077700_ehf215286-bib-0038","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin\u2013neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0039","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0040","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1002\/ejhf.1498","article-title":"Initiation of sacubitril\/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: Primary results of the randomised TRANSITION study","volume":"21","author":"Wachter","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021804142077700_ehf215286-bib-0041","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026021804142077700_ehf215286-bib-0042","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112169","article-title":"Effects of SGLT2 inhibitors on ion homeostasis and oxidative stress associated mechanisms in heart failure","volume":"143","author":"Gager","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2026021804142077700_ehf215286-bib-0043","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.999254","article-title":"Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy","volume":"9","author":"Xi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026021804142077700_ehf215286-bib-0044","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/s41569-020-0405-9","article-title":"Benefits of combination pharmacotherapy for HFrEF","volume":"17","author":"Lim","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0045","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1002\/ejhf.1351","article-title":"Medication dosing for heart failure with reduced ejection fraction\u2014Opportunities and challenges","volume":"21","author":"Marti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026021804142077700_ehf215286-bib-0046","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or rapid sequence initiation of quadruple medical therapy for heart failure\u2014Optimizing therapy with the need for speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0047","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.jchf.2024.03.001","article-title":"Eligibility and projected benefits of rapid initiation of quadruple therapy for newly diagnosed heart failure","volume":"12","author":"Greene","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026021804142077700_ehf215286-bib-0048","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2024.08.002","article-title":"Physician-reported reasons for not initiating guideline-directed medical therapy for heart failure","author":"Greene","year":"2024","journal-title":"JACC: Heart Fail"},{"key":"2026021804142077700_ehf215286-bib-0049","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1093\/eurheartj\/ehac210","article-title":"Accelerated and personalized therapy for heart failure with reduced ejection fraction","volume":"43","author":"Shen","year":"2022","journal-title":"Eur Heart J"},{"key":"2026021804142077700_ehf215286-bib-0050","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC review topic of the week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0051","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0052","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1016\/j.jacc.2023.03.426","article-title":"Uptitrating treatment after heart failure hospitalization across the spectrum of left ventricular ejection fraction","volume":"81","author":"Pagnesi","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2026021804142077700_ehf215286-bib-0053","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.919974","article-title":"Cost effectiveness analyses of pharmacological treatments in heart failure","volume":"13","author":"Lim","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2814\/66954045\/eschf_12_4_2814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/12\/4\/2814\/66954045\/eschf_12_4_2814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T09:14:30Z","timestamp":1771406070000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/12\/4\/2814\/8488108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":53,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.15286","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,15]]},"assertion":[{"value":"2024-10-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}